Description
Liquid biopsies contain cell-free DNA (cfDNA) that is found circulating in blood and isolated to the plasma component. It has been the subject of renewed attention in the scientific community recently due to easy access to genetic information that can be obtained by next generation sequencing. Two areas where cfDNA sequencing is being used are oncology and NIPT.  Circulating tumor DNA (ctDNA) derived from malignant tumors is often found within the cfDNA, and changes in quantity and composition during progression, treatment, and development of drug resistance. Sequencing of cfDNA is now being evaluated as a way to monitor the genetic evolution of metastatic cancers in response to therapy. Another use of cfDNA involves detecting fetal chromosomal aneuploidy and other abnormalities in the plasma isolated from pregnant women. Development of assays utilizing cfDNA could eliminate more invasive procedures such as amniocentesis.

Rubicon Genomics has recently developed a library preparation kit, ThruPLEX^® Plasma-seq, that is optimized specifically for cfDNA at input levels from less than 1 ng to 30 ng. This new member of the ThruPLEX product line is capable of transforming cfDNA into high complexity libraries for Illumina^® NGS platforms. The three-step single-tube workflow yields indexed libraries from purified cfDNA within 2 hours.

Join me on September 16, when we will formally launch the ThruPLEX Plasma-seq Kit.  These kits are used to create Illumina NGS libraries in three simple steps. The webinar will cover the following topics:

• The use of cell-free DNA in NIPT and oncology
• ThruPLEX technology and changes that impacted performance with cfDNA
• Creation of a library with ThruPLEX Plasma-seq
• Target enrichment with ThruPLEX Plasma-seq libraries

We will also be providing data demonstrating the performance of our new kit with cell-free DNA. This webinar will last about 40 minutes with a question and answer period following. 

Learn more about ThruPLEX Plasma-seq Kit